Effects of Pentoxifylline on the Cytokines That May Play a Role in Rejection and Resistive Index in Renal Transplant Recipients

Abstract Pentoxifylline (PTX) is a nonselective phosphodiesterase inhibitor that inhibits the production of TNFα and IL6 and IL-10 cytokines. In renal rejection TNFα, IL-6, and IL-10 may have important roles. In this study, 22 renal transplant recipients treated with tacrolimus, prednisolone, and mycophenolate mofetil were prescribed PTX (2 × 600 mg/d) for 3 months (GI), and 20 similar patients not receiving PTX were used as controls (GII). Stable subjects whose serum creatinine was lower than 1.8 mg/dL and were more than 6 months posttransplant, were enrolled into this study if the blood pressure was well controlled and there was no diabetes mellitus, infection, or inflammation. At the end of 3 months TNF-α decreased from 4.2 ± 2.1 to 2.4 ± 0.7 ( P = .001) and 4.0 ± 2.2 to 3.9 ± 1.7 ( P = .718), IL-10 also decreased from 3.90 ± 1.9 to 2.38 ± 0.6 ( P = .001) and 4.02 ± 1.6 to 3.82 ± 1.5 ( P = .225) in GI and GII, respectively. For IL-10 and TNF-α the alterations between baseline and the last visit of GI and GII were significant ( P In summary IL-10 and TNF-α levels decreased in stable recipients treated with PTx. RI also decreased marginally secondary to PTx treatment. PTx was well tolerated and free side effects. PTx did not affect tacrolimus levels or other biochemical and hematological parameters.